Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma (Q31078568)

28 June 2017

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma (English)

1 reference

28 June 2017

1 reference

Jianxin Zhao

1

1 reference

28 June 2017

Rina Wu

2

1 reference

28 June 2017

Alfred Au

3

1 reference

28 June 2017

Abbey Marquez

4

1 reference

28 June 2017

Yibing Yu

5

1 reference

28 June 2017

Zuorong Shi

6

1 reference

28 June 2017

1 June 2002

1 reference

28 June 2017

1 reference

28 June 2017

15

1 reference

28 June 2017

6

1 reference

28 June 2017

657-665

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

28 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Studies of the HER-2/neu proto-oncogene in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

C-erbB-2 immunostaining: problems with interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

The HercepTest assay: another perspective

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Testing for erbB-2 by immunohistochemistry in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Analysis of cerbB2 expression using a panel of 6 commercially available antibodies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Molecular cytogenetics of primary breast cancer by CGH

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3880582

7 January 2021

10.1038/MODPATHOL.3880582

Identifiers

DOI

1 reference

Dimensions Publication ID

28 June 2017

0 references

1 reference